3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1/2
1
Status
Active not recruiting
2
Recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
3
Head & Neck
1
Gynecologic
1
Conditions
Breast Neoplasms
243
Neoplasms
15
Neoplasm Metastasis
12
Carcinoma, Intraductal, Noninfiltrating
11
Breast Diseases
8
Advanced Breast Cancer
8
Breast Neoplasms, Male
7
Breast Carcinoma In Situ
7
Triple Negative Breast Neoplasms
5
Arthralgia
4
Ovarian Neoplasms
3
Neoplasms by Site
3
Breast Cancer Metastatic
3
Uterine Cervical Neoplasms
2
Recurrence
2
Patient Compliance
2
Osteoporosis
2
Obesity
2
Endometrial Neoplasms
2
Breast Neoplasm Female
2
Vitamin D Deficiency
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Skin Diseases
1
Sexual Dysfunctions, Psychological
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Pain
1
Nutrition Disorders
1
Interventions
Fulvestrant
4
ribociclib
3
palbociclib
3
abemaciclib
3
Anastrozole
3
selpercatinib
2
exemestane
2
Trastuzumab
2
Letrozole
2
Gonadotropin-Releasing Hormone
2
Docetaxel
2
AZD9833
2
tucatinib
1
ipatasertib
1
glutathione pegylated liposomal doxorubicin
1
entinostat
1
elacestrant
1
atezolizumab
1
alectinib
1
Zoledronic Acid
1
Watchful Waiting
1
Trabectedin
1
Tamoxifen
1
Sodium Chloride
1
STX-478
1
RAD1901
1
Paclitaxel
1
Metformin
1
Imlunestrant
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
Anastrozole
×
Breast
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled
NCT04711252
2025-10-14
SERENA-4
AstraZeneca
Phase 3
Active not recruiting
1,370 enrolled